Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Zealand Pharma AS's interest expense for the
three
months ended in Jun. 2026 was € -1.6 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Jun. 2026 was €-5.4 Mil.
Zealand Pharma AS (STU:22Z) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Zealand Pharma AS's Interest Coverage for the quarter that ended in Jun. 2026 is calculated as
GuruFocus does not calculate Zealand Pharma AS's interest coverage with the available data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Zealand Pharma AS has enough cash to cover all of its debt. Its financial situation is stable.
Zealand Pharma AS Interest Expense Historical Data
* Premium members only.
The historical data trend for Zealand Pharma AS's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zealand Pharma AS (STU:22Z) has a Interest Expense of €-5.4 Mil as of Jun. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Zealand Pharma AS and its competitors.
Is Zealand Pharma AS's Interest Expense too high?
Zealand Pharma AS's current Interest Expense is €-5.4 Mil. Overall, Zealand Pharma AS has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Interest Expense compare to VRTX and REGN?
Zealand Pharma AS's Interest Expense of €-5.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Zealand Pharma AS and its competitors. Zealand Pharma AS's current Interest Expense is €-5.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (STU:22Z) is currently considered Possible Value Trap. The stock's GF Value™ is €1,404.69, compared to a current price of €36.94 — trading 97.4% below its estimated fair value. The current Interest Expense is €-5.4 Mil. Zealand Pharma AS's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Zealand Pharma AS (STU:22Z), the current Interest Expense is €-5.4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zealand Pharma AS (STU:22Z) Overvalued in 2026?
Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued.
The current stock price of €36.94 is trading 97.4% below its estimated GF Value™ of €1,404.69.
GuruFocus considers Zealand Pharma AS to be Possible Value Trap.
Key valuation signals for STU:22Z:
Interest Expense: €-5.4 Mil
GF Value™: €1,404.69 vs. price of €36.94 (97.4% below fair value)
No single metric tells the full story. See the STU:22Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zealand Pharma A/S is a Danish biotechnology company that discovers, designs, and develops peptide-based medicines, primarily for metabolic and gastrointestinal diseases. Its pipeline includes dasiglucagon, a glucagon analog approved as Zegalogue for severe hypoglycemia and developed for congenital hyperinsulinism and bihormonal artificial pancreas systems; glepaglutide for short bowel syndrome; and survodutide, a dual GLP-1/glucagon receptor agonist licensed to Boehringer Ingelheim for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis. The company also has partnered programs with other pharmaceutical companies, generating revenue through licensing fees, milestone payments, and royalties. Zealand Pharma is headquartered in Copenhagen, Denmark, and is listed on Nasdaq Copenhagen and, through American Depositary Receipts, on Nasdaq in the United States. Its customers and collaborators are primarily large pharmaceutical companies and healthcare providers in Europe, North America, and other developed markets.
54GF Score
Get the complete analysis for STU:22Z
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:22Z has been successfully added to your 
